Seminars in arthritis and rheumatism最新文献

{"title":"Giant cell arteritis - New treatment targets at the horizon.","authors":"Jens Thiel","doi":"10.1016/j.semarthrit.2025.152686","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152686","url":null,"abstract":"<p><p>Increasing insights into the pathogenesis of giant cell arteritis (GCA) identified a large number of new treatment targets. Very recently clonal hematopoesis, immune ageing processes associated with inflammation and dysregulated immune checkpoints have been linked to the pathogenesis of GCA. Based on pathopyhsiological insights new treatment options such as Janus kinase inhibitors or IL-17A blocking antibodies are currently tested in GCA.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152686"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set","authors":"Wils Nielsen ,&nbsp;Fadi Kharouf ,&nbsp;Carolina Munoz Grajales ,&nbsp;Aarabi Thayaparan ,&nbsp;Melanie Anderson ,&nbsp;Vibeke Strand ,&nbsp;Lee Simon ,&nbsp;Dennisse Bonilla ,&nbsp;Eric Morand ,&nbsp;Julian Thumboo ,&nbsp;Martin Aringer ,&nbsp;Marta Mosca ,&nbsp;Ian Bruce ,&nbsp;Elektra J. Papadopoulos ,&nbsp;Karina D. Torralba ,&nbsp;Laura Patricia Whitall-Garcia ,&nbsp;Cheryl F. Rosen ,&nbsp;Ioannis Parodis ,&nbsp;Alfred Kim ,&nbsp;Maya Desai ,&nbsp;Zahi Touma","doi":"10.1016/j.semarthrit.2025.152684","DOIUrl":"10.1016/j.semarthrit.2025.152684","url":null,"abstract":"<div><h3>Objective</h3><div>To identify candidate Systemic Lupus Erythematosus (SLE) domains from the literature for consideration towards the development of the SLE Core Outcome Set.</div></div><div><h3>Methods</h3><div>This was a comprehensive scoping literature review of SLE clinical trials and systematic reviews published since 2010. Studies were identified from 5 databases and were screened for eligibility. Candidate domains were extracted from the included studies. Candidate domains were winnowed and binned by the Outcome Measures in Rheumatology (OMERACT) SLE Advisory Group.</div></div><div><h3>Results</h3><div>Of the 4063 studies identified, 507 met inclusion criteria and proceeded to data extraction. Multiple domains and items were extracted, which winnowing and binning reduced to 25 candidate domains.</div></div><div><h3>Conclusion</h3><div>The 25 candidate domains cover the important aspects of SLE and the 4 core areas of disease impact according to OMERACT framework. The 25 candidate domains constitute a feasible and manageable number of domains to proceed with to the core domain consensus stage that covers the wide range of impact of SLE. The candidate domains will be supplemented by ongoing qualitative research with patients living with SLE to identify additional domains before proceeding to the consensus stage.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152684"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of the 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies in anti-MDA5 antibody-positive interstitial lung disease patients: A multicenter retrospective cohort study in China","authors":"Bi Chen ,&nbsp;Bin Xi ,&nbsp;Hongxia Xin ,&nbsp;Ruyi Zou ,&nbsp;Yaqiong Tian ,&nbsp;Qi Zhao ,&nbsp;Xin Yan ,&nbsp;Xiaohua Qiu ,&nbsp;Yujuan Gao ,&nbsp;Yin Liu ,&nbsp;Min Cao ,&nbsp;Hanyi Jiang ,&nbsp;Ping He ,&nbsp;Juan Chen ,&nbsp;Hourong Cai","doi":"10.1016/j.semarthrit.2025.152700","DOIUrl":"10.1016/j.semarthrit.2025.152700","url":null,"abstract":"<div><div>The aim of this study was to assess the 2017 EULAR/ACR classification criteria performance for determining idiopathic inflammatory myopathies (IIMs) in a cohort of patients with anti-MDA5 antibody-positive IIM-related interstitial lung disease (anti-MDA5+IIM-ILD). The outcomes of patients, who did not meet the EULAR/ACR criteria, and who had interstitial pneumonia and exhibited an autoimmune phenotype associated with anti-MDA5 positivity were also investigated.</div></div><div><h3>Methods</h3><div>This retrospective study recruited adult patients from four hospitals in China who were diagnosed with anti-MDA5 antibody-positive IIM-related interstitial lung disease. Data on disease manifestations, laboratory findings, and imaging findings were collected through electronic medical records. The performance and consistency of the 2017 EULAR/ACR classification criteria were compared with those of the Bohan/Peter criteria combined with Sontheimer's CADM criteria. Additionally, this study evaluated the performance of incorporating anti-MDA5 antibodies into the EULAR/ACR criteria and explored the criteria proposed by Casal-Domingez based on myositis-specific antibodies (MSAs). Finally, clinical characteristics and prognoses were compared between patients with MDA5+IIM-ILD who met the EULAR/ACR criteria and those who did not meet the EULAR/ACR criteria.</div></div><div><h3>Results</h3><div>A total of 250 patients with anti-MDA5-related IIM-ILD, including those with dermatomyositis (DM, 23.6 %) and clinically amyopathic dermatomyositis (CADM, 76.4 %), were recruited. Of these, 175 (70 %) and 64 (25.7 %) patients met the EULAR/ACR and Bohan/Peter criteria, respectively. According to Sontheimer's CADM criteria, 60.4 % of patients could be classified according to the Bohan and Peter criteria. Thirty percent of the anti-MDA5 antibody-positive patients did not meet the EULAR/ACR criteria but met the IPAF criteria. The sensitivity of the EULAR/ACR criteria increased to 99.2 % when anti-JO-1 antibodies were replaced with anti-MDA5 antibodies. In this cohort, a sensitivity of 100 % was obtained using the Casal-Domingez criteria. There were no significant differences in clinical characteristics or prognoses between MDA5+IIM-ILD patients who met the EULAR/ACR criteria, those who did not meet the criteria, and those who met the IPAF criteria.</div></div><div><h3>Conclusion</h3><div>Approximately 30 % of clinically diagnosed anti-MDA5 antibody-positive IIM-ILD patients cannot be classified according to the EULAR/ACR criteria, suggesting that such patients should be managed as IIM-ILD patients. Modifying the existing criteria by including other MSAs, such as anti-MDA5 antibodies, as one of the scoring criteria is recommended. Future IIM guidelines should consider incorporating ILD into the diagnostic criteria.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152700"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Autoantibody response in rheumatoid arthritis; what makes it unique?","authors":"Rene E M Toes","doi":"10.1016/j.semarthrit.2025.152699","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152699","url":null,"abstract":"<p><p>Many autoimmune diseases respond well to therapies targeting B cells, emphasizing the importance of autoreactive B cells in disease induction and progression. In some cases, autoantibodies from plasma cells are the main effectors, while in others, memory B cells are thought to modulate inflammatory responses through antigen presentation or cytokine secretion. Tolerance mechanisms usually prevent the development of autoantibodies, but when these systems fail, autoimmunity and subsequent autoimmune diseases can arise. Understanding the dynamics of autoreactive B cell responses is crucial for delineation the pathogenic pathways underlying disease. Rheumatoid arthritis (RA) is a prototypic autoimmune disease featuring autoreactive B cell responses against post-translationally modified (PTM) proteins. Especially, the Anti-Citrullinated Protein Antibody (ACPA) response, the autoimmune response hallmarking RA, is well characterized over the last two decades. ACPA target citrullinated proteins and their presence is associated with more severe disease progression. In recent years, it has become apparent that ACPA are very promiscuous and able to recognize both human and microbial PTM proteins. Likewise, it is now clear that these antibodies often carry Fab glycans that could, potentially, boost B cell activation and/or be involved in evasion of tolerance mechanisms. Although subjected to tolerance checkpoint, new technologies have shown that the secreted ACPA repertoire is highly polyclonal, unique to each patient, but also dominated by a few ACPA clones. In this synopsis, these and other findings are discussed. Overall, these shed light on the complexity and evolving nature of the ACPA response in RA, unveiling new insights into autoreactive B cell behavior.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152699"},"PeriodicalIF":4.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct appearances of circulatory and secretory IgM demarcated by CD5L.","authors":"Albert J R Heck","doi":"10.1016/j.semarthrit.2025.152683","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152683","url":null,"abstract":"<p><p>IgM is an important human immunoglobulin present in our blood, but also in mucosa and body fluids such as saliva, tears and breast milk. In this manuscript Heck describes recent findings, namely that the CD5L protein is always attached to circulatory IgM but not to secretory IgM.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152683"},"PeriodicalIF":4.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B suppressor cells and protective autoantibodies.","authors":"Rikard Holmdahl","doi":"10.1016/j.semarthrit.2025.152687","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152687","url":null,"abstract":"<p><p>Recently the importance of B cells has been highlighted for therapy of several autoimmune diseases including rheumatoid arthritis (RA). Still, the functional role of B cells and antibodies in the disease process are unclear. Using animal models, antibodies specifically binding cartilage are pathogenic, but it has also recently been shown that both B cells and antibodies could be protective. These have specificities that are similar to B cells and autoantibodies detected in humans, including antibodies to citrullinated proteins and collagen type II, and may play an important role hindering an inflammatory attack, whereafter pathogenic B cells and antibodies are functionally more important to initiate and drive the clinically observable disease.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152687"},"PeriodicalIF":4.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the Wnt pathway for the treatment of Osteoarthritis of the knee.","authors":"Nancy E Lane","doi":"10.1016/j.semarthrit.2025.152662","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152662","url":null,"abstract":"<p><p>Both epidemiologic and preclinical models of OA provide strong support for modulation of the Wnt signaling pathway as a druggable target for painful knee OA. This paper reviews the clinical studies that have been performed with Wnt signaling modulating agents for knee OA treatment and makes recommendations to study earlier disease and administer treatments for a longer duration.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152662"},"PeriodicalIF":4.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematopoietic stem cell transplant, chimeric antigen receptor T-cells, and other cellular therapies as stepping stones toward long-term improvement in severe scleroderma and other autoimmune diseases.","authors":"Keith M Sullivan","doi":"10.1016/j.semarthrit.2025.152676","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152676","url":null,"abstract":"<p><p>Preclinical models of inherited and induced autoimmune diseases (AIDs) have shown that hematopoietic stem cell transplantation (HSCT) following high-dose immunosuppressive conditioning could reverse organ damage and alter the course of AIDs. The rationale for both autologous and allogeneic HSCT has been based upon a reset of the immune system. Clinical application of HSCT was initially focused on severe systemic sclerosis (SSc) and three randomized trials comparing autologous HSCT with standard cyclophosphamide (CY) demonstrated significant improvement in SSc measured 12-54 months after transplant. Meta-analysis of the three trials showed the relative risk of all-cause mortality after HSCT was 0.5 compared to CY. More recently, clinical improvements in several AIDs have been reported with CY/fludarabine preparation followed by CD19 chimeric antigen receptor (CAR) T-cell infusion. With follow-up of 4-29 months, major disease responses and full B-cell reconstitution have been observed while side effects have been modest. Industry and academic centers are active in developing these and other cellular products for AID treatments including CAR-NK, off the shelf CAR-Ts, chimeric autoantibody receptor (CAAR-Ts), and mesenchymal stromal cells (MSCs). Clinical improvements after MSC administration have been reported, but as with the CAR-T trials, follow-up is still brief. Shared decision making with patients considering cellular therapy is perhaps easier for autologous HSCT since we have longer follow-up with many patients clinically improved and surviving off DMARDS for decades. Such individuals understandably view themselves as cured. Thus, the interest in the evolving role of cellular therapies in long-term improvement in severe AIDs.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152676"},"PeriodicalIF":4.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Probing the synovium-brain axis.","authors":"Neil Basu","doi":"10.1016/j.semarthrit.2025.152673","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152673","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152673"},"PeriodicalIF":4.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk and triggering factors for diffuse alveolar hemorrhage in primary antiphospholipid syndrome. An observational follow-up study and a systematic review of the literature","authors":"Amelia Ruffatti ,&nbsp;Marta Tonello ,&nbsp;Maria Favaro ,&nbsp;Teresa Del Ross ,&nbsp;Antonia Calligaro ,&nbsp;Ariela Hoxha ,&nbsp;Giovanni Peronato ,&nbsp;Cesarina Facchini ,&nbsp;Margherita Zen ,&nbsp;Renzo Manara","doi":"10.1016/j.semarthrit.2025.152697","DOIUrl":"10.1016/j.semarthrit.2025.152697","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Diffuse alveolar hemorrhage (DAH) represents a serious, life-threatening complication of primary antiphospholipid syndrome (PAPS), a thrombophilic disorder mainly characterized by vascular thrombosis and/or pregnancy morbidity. Risk factors for DAH in PAPS patients and the comorbidities that may trigger DAH were investigated here in the effort to identify possible independent predictors of DAH in PAPS patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Only PAPS patients fulfilling the Sydney criteria were taken into consideration. The DAH diagnosis was based on the patient's clinical presentation (acute illness manifesting with dyspnoea, hypoxia, cough, anemia and less frequently hemoptysis and fever), the presence of transient lung infiltrates on chest radiographs, a rapidly changing ground-glass appearance on computed tomography, and a positive response to high dose steroid therapy prescribed during an acute phase. The PAPS patients manifesting DAH signs and symptoms were considered the study group; the remaining served as the control group. The following comorbidities were investigated: i) left-sided heart valve diseases, ii) left heart failure and iii) hemolytic anemia. The clinical and laboratory characteristics and comorbidities of the PAPS-associated DAH patients were recorded and compared with those of the control group and those of the PAPS-associated DAH patients identified by a literature review.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The subjects considered for inclusion were 197 PAPS patients (142 women and 55 men) all suffering from thrombosis, which was associated with pregnancy morbidity in 30 (21.1 %) of the women. Eight (4.1 %) of these patients (five men and three women) experienced one or more episodes of DAH. When the clinical and laboratory characteristics of the PAPS-associated DAH patients were compared with those of the controls a significant prevalence of the male gender (&lt;em&gt;p&lt;/em&gt; = 0.0399), of the multiple types of vascular involvement profile (&lt;em&gt;p&lt;/em&gt; = 0.0048) and of high antiphospholipid antibody (aPL) titers (&lt;em&gt;p&lt;/em&gt; = 0.0011) was noted in the former. Triple aPL positivity and microcirculation thrombosis were also more frequent in that group, although not to a significant degree. The prevalence of comorbidities including left-sided heart valve diseases, left heart failure and hemolytic anemia was likewise significantly higher in the PAPS-associated DAH patients (&lt;em&gt;p&lt;/em&gt; = 0.0253, 0.0451 and 0.0358, respectively). According to logistic regression analysis, multiple types of vascular involvement profile, left-sided heart valve diseases and hemolytic anemia were found to be independent risk factors for DAH (&lt;em&gt;p&lt;/em&gt; = 0.030, 0.022 and 0.007, respectively). Twenty-four studies (one case-control, three small case series, and 20 case reports) reporting on 55 PAPS-associated DAH patients were identified by a review of the literature. The clinical and laboratory characteristics and comorb","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152697"},"PeriodicalIF":4.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}